title: Serum human telomerase reverse transcriptase messenger RNA as a novel tumor marker for hepatocellular carcinoma.
abstract: OBJECTIVE
  We previously reported the usefulness of a qualified highly sensitive detection method for human telomerase reverse transcriptase (hTERT) mRNA in serum with 89.7% sensitivity for hepatocellular carcinoma (HCC). In this study, we developed a quantitative detection method for serum hTERT mRNA and examined the clinical significance in HCC diagnosis. EXPERIMENTAL BACKGROUND: In 64 patients with HCC, 20 with liver cirrhosis, 20 with chronic hepatitis, and 50 healthy individuals, we measured serum hTERT mRNA by using the newly developed real-time quantitative reverse transcription-PCR with SYBR Green I. We examined its sensitivity and specificity in HCC diagnosis, clinical significance in comparison with other tumor markers, and its correlations with the clinical variables by using multivariate analyses.
  
  
  RESULTS
  Serum hTERT mRNA showed higher values in patients with HCC than those with chronic liver diseases. hTERT mRNA expression was shown to be independently correlated with clinical variables such as tumor size, number, and degree of differentiation (P < 0.001, each). The sensitivity/specificity of hTERT mRNA and alpha-fetoprotein (AFP) mRNA in HCC diagnosis were 88.2%/70.0% for hTERT and 71.6%/67.5% for AFP, respectively. hTERT mRNA proved to be superior to AFP mRNA, AFP, and des-gamma-carboxy prothrombin in HCC diagnosis. Furthermore, hTERT mRNA in serum was associated with that in HCC tissue.
  
  
  CONCLUSIONS
  The usefulness of hTERT mRNA expression in HCC diagnosis and its superiority to conventional tumor markers were shown. Therefore, serum hTERT mRNA is a novel and available marker for HCC diagnosis.
authors.affiliation: Division of Pharmacotherapeutics, Department of Pathophysiological and Therapeutic Science, Tottori University School of Medicine, Yonago, Japan. mnmiura@grape.med.tottori-u.ac.jp
authors.forename: Norimasa
authors.initials: N
authors.lastname: Miura
authors.forename: Yoshiko
authors.initials: Y
authors.lastname: Maeda
authors.forename: Takamasa
authors.initials: T
authors.lastname: Kanbe
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Yazama
authors.forename: Yohei
authors.initials: Y
authors.lastname: Takeda
authors.forename: Reina
authors.initials: R
authors.lastname: Sato
authors.forename: Tomoe
authors.initials: T
authors.lastname: Tsukamoto
authors.forename: Emi
authors.initials: E
authors.lastname: Sato
authors.forename: Akira
authors.initials: A
authors.lastname: Marumoto
authors.forename: Tomomi
authors.initials: T
authors.lastname: Harada
authors.forename: Akiko
authors.initials: A
authors.lastname: Sano
authors.forename: Yosuke
authors.initials: Y
authors.lastname: Kishimoto
authors.forename: Yasuaki
authors.initials: Y
authors.lastname: Hirooka
authors.forename: Yoshikazu
authors.initials: Y
authors.lastname: Murawaki
authors.forename: Junichi
authors.initials: J
authors.lastname: Hasegawa
authors.forename: Goshi
authors.initials: G
authors.lastname: Shiota
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood*; D006528:Carcinoma, Hepatocellular / Q000097:blood / Q000175:diagnosis* / Q000235:genetics; D004268:DNA-Binding Proteins; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000235:genetics; D008297:Male; D008875:Middle Aged; D012333:RNA, Messenger / Q000097:blood; D020133:Reverse Transcriptase Polymerase Chain Reaction / Q000379:methods; D012680:Sensitivity and Specificity; D019098:Telomerase / Q000235:genetics*
chemical_list: D014408:Biomarkers, Tumor; D004268:DNA-Binding Proteins; D012333:RNA, Messenger; D019098:Telomerase